Phaseline

Companies › ImmuneOncia Therapeutics

ImmuneOncia Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 1; Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Danburstotug (IMC-001)
Programmed cell death 1 ligand 1 inhibitor
CD274Phase 2Extranodal NK/T-cell Lymphoma, Nasal Type; TMB-H; Subjects With Resectable and Localized Gastric CancerFeb 2027
IMC-002–Phase 1Advanced CancerDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04414163Danburstotug (IMC-001)Phase 2Extranodal NK/T-cell Lymphoma, Nasal TypeOncologyFeb 2027
NCT06365840Danburstotug (IMC-001)Phase 2TMB-HOncologyJun 2027
NCT05276310IMC-002Phase 1Advanced CancerOncologyDec 2027
NCT04196465Danburstotug (IMC-001)Phase 2Subjects With Resectable and Localized Gastric CancerOncologySep 2028

Targets

CD274 (1)

Companies with the same targets

AstraZeneca Pfizer IO Biotech Akeso Roche Biotheus Suzhou Suncadia Biopharmaceuticals Shine-On Biomedical 3D Medicines (Sichuan) Shanghai Henlius Biotech

Companies built like this

3D Medicines (Sichuan) InxMed (Shanghai) Lantheus Medical Imaging Newish Biotech (Wuxi) Zhejiang Hisun Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.